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Purpose: Levofloxacin has been widely used because of its broad spectrum and excellent 
penetration of the prostate. But levofloxacin-resistant Escherichia coli (E.coli) has been 
reported all over the world. We analyzed the annual levofloxacin resistance of E. coli
and its risk factors.
Materials and Methods: From 2005 to 2009, we retrospectively analyzed patients who 
had undergone a urine analysis and a urine culture at the Outpatient Section of the 
Department of Urology of Kwangju Christian Hospital. Among them, we chose 509 pa-
tients infected by E. coli and evaluated the resistance rate to levofloxacin and its risk 
factors.
Results: The annual rates of levofloxacin resistance of E. coli were 29.49% in 2005, 
26.51% in 2006, 40.21% in 2007, 43.20% in 2008, and 31.75% in 2009. A close correlation 
with the resistance rate was shown in cases that had underlying neurogenic bladder 
(p=0.002, odds ratio [OR]=4.236), a history of ciprofloxacin (p＜0.001, OR=3.753) and 
levofloxacin (p＜0.001, OR=2.996) administration for at least 48 hours in the past year, 
urolithiasis (p=0.003, OR=3.317), and older age (p＜0.001, OR=1.027). 
Conclusions: This study from 2005 to 2009 showed that the levofloxacin resistance rates 
of E. coli were high at over 25%. The risk factors that affected the levofloxacin resistance 
rates of E. coli were underlying neurogenic bladder, ciprofloxacin administration his-
tory, urolithiasis, levofloxacin administration history, and older age. Levofloxacin 
should be prescribed cautiously in patients with these risk factors until the pathogen 
is identified.
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INTRODUCTION
Cephalosporin and penicillin antibiotics were used to be 
the primary prescriptions for infections in the past. After 
the increase in resistant strains against these antibiotics, 
quinolone-class antibiotics emerged. According to IMS 
Health statistics, sales of quinolones reached approx-
imately 151.3 billion won in the fourth quarter of 2010 in 
South Korea [1]. Sales of ciprofloxacin in the fourth quarter 
of 2010 increased by 75% to about 64.5 billion won  over the 
same period in 2004, whereas sales of levofloxacin in-
creased by 195% to about 62.1 billion won (Fig. 1) [1]. The 
rapid increase in sales of levofloxacin is attributed to its 
broader antimicrobial spectrum compared with that of 
ciprofloxacin. Levofloxacin has been widely used world-
wide, while reports of levofloxacin-resistant Escherichia 
coli (E. coli) have surfaced. Domestic studies on cipro-
floxacin resistance have been reported several times, but 
there have been few studies on resistance to levofloxacin 
amid the recent increase in its usage. Therefore, we per-
formed this study to support the choice of antibiotics before 
the identification of the pathogen in treating urinary tract 
infection (UTI). We studied outpatients whose urine cul-
ture results had been identified with E. coli, the most com-
mon causative pathogen of UTI, within the past 5 years and 
analyzed the annual levofloxacin resistance of E. coli and Korean J Urol 2011;52:554-559
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FIG. 1. Variations in sales amounts of ciprofloxacin and 
levofloxacin in South Korea. 4Q: the fourth quarter.
its risk factors.
MATERIALS AND METHODS
1. Inclusion and exclusion criteria
E. coli was isolated from 701 of the 8,063 patients who had 
visited the Outpatient Section of the Department of 
Urology of Kwangju Christian Hospital and had undergone 
a urine culture test from January 2005 to December 2009. 
Patients who had repeatedly undergone urine culture tests 
in the same year were excluded. E. coli was determined as 
the causative pathogen if the amount of the isolated E. coli 
colony was over 10
5 counts per ml of voided urine or was 
over 10
3 counts per ml of catheterized urine. The subjects 
of this study were 509 patients who met the afore-
mentioned inclusion and exclusion criteria. The patients’ 
mean age was 55.1±17.3 years. The ratio of males to fe-
males was 1.0 to 5.8.
2. Methods of urine collection and urine test
Urine sample collection was performed by the following 
methods. For patients with a urinary catheter, urine was 
collected by using a sterilized syringe after the tip of the 
catheter was washed with a boric sponge. For patients 
without a urinary catheter and who could self-urinate, 
their midstream urine was collected after the opening of 
their urethra and its surroundings were washed with a bor-
ic sponge. For pediatric patients who could not control their 
urination, urine was collected after the opening of their 
urethra and its surroundings were washed with a boric 
sponge and a feeding tube was inserted through the ure-
thra to the bladder. 
　The collected urine samples were gram-stained for mi-
croscopic observation, and 0.001 ml of each sample was in-
oculated on a serum agar medium and a MacConkey agar 
medium for culture at 37°C for 24 to 48 hours. Pathogen 
identification was conducted by using MicroScan
Ⓡ of 
Siemens, and the antibiotic sensitivities were determined 
by using the minimum inhibitory concentration.
3. Various risk factors
Retrospective analyses were performed for the sex and age 
of the patients, their antibiotic sensitivity against E. coli, 
and various clinical factors. The patients were categorized 
according to age: under 10, 10 to 19, 20 to 29, 30 to 39, 40 
to 49, 50 to 59, 60 to 69, 70 to 79, and over 79 years. The 
clinical factors included underlying diseases, medical his-
tories, and status of the urinary catheterization of the pa-
tients at the time of their hospital visit. The underlying dis-
eases were diabetes mellitus, hypertension, urinary incon-
tinence, benign prostatic hyperplasia, urolithiasis, neuro-
genic bladder, digestive diseases, cerebrovascular dis-
eases, and arthritis. The checked medical histories in-
volved levofloxacin, ciprofloxacin, and antibiotics except 
for quinolone administration for at least 2 days in the past 
12 months, regardless of the disease, hospitalization, expe-
rience of urological surgery and surgery besides urological 
surgery, and UTI. Also, the insertion of a Foley catheter, 
the insertion of a percutaneous nephrostomy (PCN) tube, 
and the use of clean intermittent catheterization (CIC) 
were checked at the time of the patient’s hospital visit.
4. Statistical analysis
To examine the annual variations in resistance of E. coli 
to levofloxacin in the outpatients, the mean values in the 
levofloxacin-resistant cases were compared among those 
who had been identified as having E. coli in their urine cul-
ture test each year from 2005 to 2009 via ANOVA. In addi-
tion, to explore the correlation of the levofloxacin resist-
ance of E. coli with various risk factors, the risk factors and 
the levofloxacin-resistant or levofloxacin-susceptible pa-
thogens were cross-tabulated against E. coli (the chi-squ-
are method). Logistic regression analysis was used to de-
termine whether there was a significant correlation be-
tween the factors that showed differences in the cross-tabu-
lation with the levofloxacin resistance of E. coli. SPSS ver. 
12.0 (SPSS Inc., Chicago, IL, USA) was used as the stat-
istical analysis program, and a p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Levofloxacin-resistant E. coli was identified in the anti-
biotic susceptibility test in 178 of the 509 patients (34.97%). 
E. coli was identified in the urine culture test in 75 male 
patients from among the 509 patients (14.70%); of these 75 
males, levofloxacin-resistant E. coli was identified in 32 
males (42.70%). E. coli was identified in the urine culture 
test in 434 female patients from among the 509 patients 
(85.30%); of these 434 females, levofloxacin-resistant E. 
coli was identified in 146 females (33.60%). The annual 
rates of resistance of E. coli to levofloxacin were 23 among 
78 patients (29.49%) in 2005, 22 among 83 patients 
(26.51%) in 2006, 39 among 97 patients (40.21%) in 2007, Korean J Urol 2011;52:554-559
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TABLE 1. Annual levofloxacin resistance rate of E. coli 
Years 2005 2006 2007 2008 2009
No. of total patients
No. of patients with levo-
floxacin-resistant E. coli
Resistance rate (%)
78
23
29.49
83
22
26.51
97
39
40.21
125
54
43.20
126
40
31.75
TABLE 2. Levofloxacin resistance rate of E. coli according to age
Age (yr) No. of patients Resistance rate (%)
0-10
10-19
20-29
30-39
40-49
50-59
60-69
70-79
80-
10
5
27
62
63
113
115
90
24
0.00
20.00 
25.93 
14.52 
28.57 
34.51 
42.61 
43.33 
66.67 
Total 509 34.97 
TABLE 3. Levofloxacin resistance rate of E. coli according to 
various risk factors
Various risk factors
Resistance rate (%)
Risk group No-risk group
Medical history
　Levofloxacin administration
　Ciprofloxacin administration
　Other antibiotics administration
　Hospitalization
　Urological surgery
　Other surgery
　Urinary tract infection 
Underlying disease
　Diabetes mellitus
　Hypertension
　Urinary incontinence
　Benign prostatic hyperplasia
　Urolithiasis
　Neurogenic bladder
　Digestive disease
　Cerebrovascular disease
　Arthritis
Status of urinary catheterization
　Catheter 
CIC
65.96 
68.12 
40.65 
45.71 
42.86 
37.89 
42.11 
48.44 
43.90 
46.30 
48.78 
65.79 
79.49 
33.33 
60.87 
45.83 
84.21 
81.82 
27.95 
29.77 
32.49 
32.18 
34.39 
33.62 
33.33 
33.03 
32.12 
33.63 
33.76 
32.48 
31.28 
35.34 
32.40 
34.43 
33.06 
33.94 
Catheter: state of Foley catheterization, percutaneous neph-
rostomy (PCN), or cystostomy, CIC: clean intermittent catheter-
ization
TABLE 4. Logistic regression analysis of risk factors for 
levofloxacin resistance of E. coli 
Variables OR (95% CI) p-value
Aging
Levofloxacin administration
  history
Ciprofloxacin administration
  history
Admission history
Catheter
CIC
Diabetes mellitus
Hypertension
Urolithiasis
Neurogenic bladder 
Cerebrovascular diseases
1.027 (1.012-1.042)
2.996 (1.704-5.266)
3.753 (1.991-7.075)
0.809 (0.463-1.412)
2.715 (0.658-11.206)
1.205 (0.208-6.977)
1.216 (0.637-2.319)
0.920 (0.538-1.572)
3.317 (1.520-7.238)
4.236 (1.667-10.767)
1.665 (0.780-3.555)
＜0.001
＜0.001
＜0.001
0.456
0.167
0.835
0.553
0.759
0.003
0.002
0.187
Catheter: state of Foley catheterization, percutaneous neph-
rostomy (PCN), or cystostomy, CIC: clean intermittent catheter-
ization
54 among 125 patients (43.20%) in 2008, and 40 among 126 
patients (31.75%) in 2009. These figures did not increase 
with statistical significance given the set 0.05 significance 
level (p=0.058), but all the resistance rates were over 25%, 
which was high (Table 1). In the older patients, the resist-
ance rates were high (Table 2).  The levofloxacin resistance 
rates of E. coli according to other various risk factors were 
calculated (Table 3). Statistically significant differences 
were shown in the following via cross-tabulation: older age; 
cases with levofloxacin and ciprofloxacin administration 
history for at least 48 hours in the past year, and with a his-
tory of hospitalization; maintenance of a Foley catheter, 
PCN tube, cystostomy tube, or CIC at the time of the hospi-
tal visit; and underlying diseases such as diabetes mellitus, 
hypertension, urolithiasis, neurogenic bladder, and cere-
brovascular diseases. Via logistic regression analysis, a 
close correlation with levofloxacin-resistant E. coli was 
shown in the cases that had underlying neurogenic bladder 
(p=0.002, odds ratio [OR]=4.236), a history of ciprofloxacin 
(p＜0.001, OR=3.753) and levofloxacin (p＜0.001, OR= 
2.996) administration for at least 48 hours in the past year, 
urolithiasis (p=0.003, OR=3.317), and older age (p＜0.001, 
OR=1.027) (Table 4). In the cases of underlying neurogenic 
bladder, the odds ratio was 4.236, which showed the high-
est statistical correlation with levofloxacin-resistant E. 
coli.
　The reasons for the high rates of levofloxacin-resistant 
E. coli in 2007 and 2008 were analyzed. A close correlation 
with the occurrence of levofloxacin-resistant E. coli was an-
ticipated in the analysis of the patients with neurogenic 
bladder and ciprofloxacin and levofloxacin administration 
history. The hospital visit rates of the patients with neuro-
genic bladder from 2005 to 2009 were 2.56%, 8.43%, 9.28%, 
9.60%, and 7.14%, respectively, and were especially high 
in 2007 and 2008. In the patients who had taken levo-
floxacin, the hospital visit rates were 11.54%, 15.66%, 
20.62%, 21.60%, and 19.84% from 2005 to 2009, respec-
tively. In the patients who had taken ciprofloxacin, the hos-
pital visit rates were 7.69%, 7.23%, 16.49%, 19.20%, and 
13.49% from 2005 to 2009, respectively, with high rates 
seen in the patients with risk factors in 2007 and 2008.Korean J Urol 2011;52:554-559
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TABLE 5. Variations in resistance rates of E. coli to antibiotics
Resistance rate (%), Years
2005 2006 2007 2008 2009
　Ampicillin
　Ampicillin/Sulbactam
　Cefazolin
　Cefuroxime
　Cefotetan
　Ceftriaxone
　Ceftazidime
　Cefotaxime
　Cefepime
　Trimethoprime/Sulfamethoxazole
　Ciprofloxacin
　Levofloxacin
　Moxifloxacin
　Gentamicin
　Amikacin
　Tobramycin
　Aztreonam
　Imipenem
　Meropenem
　Piperacillin/Tazobactam
　Ticarcillin/K clavulanate
66.67 
62.82 
23.08 
14.10 
3.85 
7.69 
3.85 
7.69 
7.69 
41.03 
28.21 
29.49 
29.49 
26.92 
8.97 
29.49 
11.54 
1.28 
28.21 
11.54 
21.79 
62.65 
61.45 
22.89 
16.87 
8.43 
4.82 
3.61 
3.61 
6.02 
30.12 
22.89 
26.51 
37.35 
30.12 
6.02 
30.12 
14.46 
4.82 
14.46 
22.89 
12.05 
74.23 
70.83 
37.50 
27.08 
12.50 
18.56 
15.63 
17.53 
13.54 
38.54 
42.27 
40.21 
39.58 
32.99 
6.25 
37.50 
21.65 
3.09 
3.13 
13.54 
28.13 
71.20 
65.60 
33.60 
25.60 
8.00 
16.00 
16.80 
16.80 
16.00 
43.20 
44.80 
43.20 
40.00 
27.20 
4.80 
25.60 
22.40 
4.00 
2.40 
16.80 
21.60 
65.08 
62.70 
19.05 
14.29 
4.76 
9.52 
9.52 
9.52 
7.94 
31.75 
34.13 
31.75 
32.79 
26.98 
3.17 
26.98 
10.32 
1.59 
1.59 
7.94 
16.67 
　The resistance rates of E. coli to antibiotics other than 
levofloxacin were also analyzed (Table 5). The annual re-
sistance rates to ciprofloxacin from 2005 to 2009 were 
28.2%, 22.9%, 42.3%, 44.8%, and 34.1%, respectively; for 
moxifloxacin, they were 29.5%, 37.4%, 39.6%, 40.0%, and 
32.8%, respectively. They were all above 20%. Ampicillin 
and ampicillin/sulbactam had the highest resistance rate 
of over 60%. Trimethoprim/sulfamethoxazole (TMP-SMX) 
showed resistance rates of 41.0%, 30.1%, 38.5%, 43.2%, and 
31.8%, respectively; cefazolin, a first-generation cepha-
losporin, had a relatively higher resistance rate than the 
third-generation cephalosporins. Gentamicin showed re-
sistance rates of 26.9%, 30.1%, 33.0%, 27.2%, and 27.0%, 
respectively; tobramycin, 29.5%, 30.1%, 37.5%, 25.6%, and 
27.0%, respectively; and amikacin, 9.0%, 6.0%, 6.3%, 4.8%, 
and 3.2%, respectively. Among the cabarpenem-class anti-
biotics, aztreonam had resistance rates of 11.5%, 14.5%, 
21.7%, 22.4%, and 10.3%, respectively; imipenem, 1.3%, 
4.8%, 3.1%, 4.0%, and 1.6%, respectively; and meropenem, 
28.2%, 14.5%, 3.1%, 2.4%, and 1.6%, respectively. The anti-
biotics with E. coli resistance rates that were lower than 
20% from 2007 to 2009 were cefotetan, ceftriaxone, ceftazi-
dime, cefotaxime, cefepime, amikacin, piperacillin/t azo-
bactam, imipenem, and meropenem (Table 5).
DISCUSSION
E. coli, the most prevalent pathogen of UTI, had been sus-
ceptible to ampicillin and amoxicillin, but the widespread 
use of these β-lactam antibiotics is associated with the 
emergence of resistant strains. Resistance to these agents 
is usually mediated by the production of β-lactamases, 
which inactivate these antibiotics [2]. According to a do-
mestic report, ampicillin resistance rates of E. coli were 
70% in 2005 and 71% in 2006 among outpatients [3].
　TMP-SMX, which has been used to treat UTI, com-
petitively inhibits folate synthetic enzymes. TMP-SMX-re-
sistant E. coli bypasses the inhibition by generating in-
sensitive targets [4]. The resistance rate of TMP-SMX had 
already reached a serious level in the United States, and, 
thus, alternatives are essential for at least certain areas. 
Lee et al reported in 2003 that the domestic resistance rate 
to TMP-SMX was 38.7%, which means that TMP-SMX can 
no longer be used for first-line treatment of uncomplicated 
UTI [5].
　Since empirical first-line therapy with TMP-SMX be-
came more difficult due to the increase in the resistant 
pathogens of UTI, the Infectious Disease Society of 
America (IDSA) suggested guidelines [6]. According to the 
IDSA guidelines, fluoroquinolone should be the empirical 
first-line choice for the treatment of uncomplicated UTI if 
the resistance rate of E. coli to TMP-SMX exceeds 20% in 
a territory. Thus, fluoroquinolones are suggested as alter-
natives for the empirical first-line treatment of un-
complicated UTI, and they are commonly prescribed 
worldwide. Despite the disadvantages of fluoroquinolone, 
such as their high price and contraindication in pediatric 
patients, they have been used for first-line treatment of 
UTI because gram-negative pathogens are very suscep-
tible to them and fewer pathogens are resistant to them 
compared with other drugs. Fluoroquinolone, which in-
hibits DNA gyrase (topoisomerase II) to interrupt the DNA Korean J Urol 2011;52:554-559
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synthesis of bacteria, has been known to be associated with 
very rare resistance cases that developed by natural muta-
tion in vitro. The issue has surfaced, however, because of 
the recent increase in E. coli resistance to ciprofloxacin [7]. 
The decrease in fluoroquinolone susceptibility is known to 
have developed via the mutation of parC and gyrA, which 
code topoisomerase enzymes, which affects the cell efflux 
mechanism to primarily lower the intracellular drug accu-
mulation [8].
　According to statistical data from IMS Health, a speci-
alized consulting firm for the health care and pharmaceut-
ical sectors, domestic sales of quinolones reached 151.352 
billion won in the fourth quarter of 2010, with ciprofloxacin 
and levofloxacin accounting for approximately 84% at 
64.451 billion won and 62.098 billion won, respectively [1]. 
Among fluoroquinolones, ciprofloxacin has been pre-
scribed most frequently so far; but the ciprofloxacin resist-
ance rate of E. coli has been reported as 20% in Brazil, 20% 
in Spain, and 26% in Europe [9-11]. In South Korea, cipro-
floxacin has been widely prescribed for the treatment of 
UTI, and the resistance rate due to its increased use and 
abuse has increased. Ko et al reported that the suscepti-
bility of Gram-negative bacteria to ciprofloxacin was 87.8% 
in 1994 and 78.8% in 1998 [12]. Song and Kim reported that 
E. coli had been identified in 46.4% of 584 hospitalized pa-
tients and 305 outpatients with UTI, whereas the cipro-
floxacin resistance rate was 19.8% and 18.8%, respectively, 
in 2003 [13]. Ryu et al also reported that the ciprofloxacin 
resistance rate of E. coli had increased from 46.8% to 52.5% 
among hospitalized patients and from 27.2% to 34.9% 
among outpatients in 2000 and 2005, respectively [14]. The 
ciprofloxacin resistance rate has already reached a serious 
level.
　Levofloxacin has been reported to have excellent anti-
microbial activity and to be effective for both Gram-positive 
bacteria and anaerobes, compared to ciprofloxacin [15,16]. 
Thus, it has recently been used to treat H. pylori infection 
and pneumonia and to prevent infections in hepatobiliary 
surgeries [17-19]. Especially in urology, with the emerging 
importance of Gram-positive bacteria such as Enterococ-
cus faecalis and Staphylococcus epidermidis, as well as of 
Gram-negative enterobacteria including E. coli, which is 
the causative pathogen of bacterial prostatitis, levoflox-
acin has become the standard therapy in the treatment of 
chronic bacterial prostatitis [20,21]. In the United States, 
between 1998 and 2005, however, as prescriptions of levo-
floxacin increased from 3.1 to 12.7 prescriptions per 1000 
outpatient visits, the rate of levofloxacin-resistant E. coli 
increased from 1% to 9%. The switch to levofloxacin for the 
initial management of outpatient UTI was followed by the 
rapid emergence of levofloxacin-resistant E. coli [22]. 
According to a Japanese report in 2008, four sepsis cases 
caused by levofloxacin-resistant E. coli had been reported 
among 665 patients upon ultrasound-guided transrectal 
prostate biopsy from July 2002 to December 2006. The au-
thors suggested that fluoroquinolone-resistant E.coli in-
fection after ultrasound-guided transrectal prostate biop-
sy might be increasing due to the widespread use of fluo-
roquinolones in both humans and food animals [23]. 
　In South Korea, the levofloxacin resistance rate may be 
increasing as the use of levofloxacin has increased. 
Excluding 2007 and 2008, in which the percentage of pa-
tients with significant risk factors in this study was high, 
the levofloxacin resistance rate of E. coli increased through 
the years. The outcome of this study does not exactly repre-
sent the levofloxacin resistance rate of E. coli in South 
Korea, however, because this study was conducted at a sin-
gle hospital in only one community from 2005 to 2009. To 
confirm the levofloxacin resistance rate of E. coli in South 
Korea, combined data from multiple community health 
center sites are required.
CONCLUSIONS
Although ciprofloxacin resistance of E. coli has been re-
ported, reports on the levofloxacin resistance rate for over 
5 years and its correlation to risk factors are rare. Thus, we 
studied the resistance of E. coli to levofloxacin, the chem-
ical structure of which is unlike that of ciprofloxacin, even 
though they belong to the same class of fluoroquinolones. 
In addition, various factors related to the levofloxacin re-
sistance rate of E. coli were investigated by using statistical 
analysis. The levofloxacin resistance rates of E. coli were 
high at over 25% from 2005 to 2009. The results of the re-
gression analysis showed that the factors that affected the 
resistance rate were an underlying neurogenic bladder, ci-
profloxacin administration history, urolithiasis, levo-
floxacin administration history, and older age. For pa-
tients who have risk factors for levofloxacin resistance, as 
analyzed in this study, levofloxacin should be cautiously 
prescribed until the pathogen is identified. In such cases, 
prescription of other antibiotics that have lower resistance 
rates should be considered.
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